Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?

Autor: Claude Le Pen, Pascal Paubel, Martine Sinègre, Olivier Parent de Curzon, Albane Degrassat-Théas

Publikováno v: PharmacoEconomics
PharmacoEconomics, 2013, 31 (4), ⟨10.1007/s40273-013-0039-4⟩
PharmacoEconomics, 2013, 31 (4), 〈10.1007/s40273-013-0039-4〉

International audience; BackgroundTo reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2864719e994349072eef21fec0623647
https://doi.org/10.1007/s40273-013-0039-4

Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis

Autor: François Bocquet, Isabelle Fusier, Martine Sinègre, Pascal Paubel, Anne-Laure Cordonnier, Claude Le Pen

Publikováno v: Applied Health Economics and Health Policy
Applied Health Economics and Health Policy, Adis, 2014, 12 (3), ⟨10.1007/s40258-014-0087-8⟩
Applied Health Economics and Health Policy, Adis, 2014, 12 (3), 〈10.1007/s40258-014-0087-8〉

International audience; BackgroundBiosimilars are copies of biological reference medicines. Unlike generics (copies of chemical molecules), biologics are complex, expensive and complicated to produce. The knowledge of the factors affecting the compet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7b322f273d8f317eadf539ba975fdc1
https://hal.archives-ouvertes.fr/hal-01507475